Sandbox Reserved 957

spinqualitylabelsall models Insert caption here Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975.

To get started: Click the edit this page tab at the top. Save the page after each step, then edit it again. Click the 3D button (when editing, above the wikitext box) to insert Jmol. show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page. Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc. More help: Help:Editing

IntroductionIntroduction

PDE5, phosphodiesterase 5 (EC 3.1.4.35), is an abundant protein in cell of airway and visceral smooth muscle and vascular cell. It can be found in epithelial cell and in Purkinje cell of the cerebella [1] and platelets and Corpus Cavernosum. In particular, it is implied in the NO pathway of penile erection and so in the Erectile Dysfunction (ED) [22].
There are 11 families of PDE (from 1 to 9), there is 21 genes for PDE which code 60 different PDE. For the PDE5A, the only PDE5 subcategory, there are 4 isoforms but their catalytic domain is the same [24].
The catalytic reaction is the hydrolysis of guanosine cyclic monophosphate into linear guanosine monophosphate. This cGMP-specific enzyme have 3 domains (from N terminal to C terminal) : GAF A, GAF B and a conserved catalytic domain regard to other PDEs of the family. Only cGMP can bind GAF A or GAF B and it stimulates the hydrolysis.
We study here the PDE5A catalytic fragment formed of amino acid residues from the 535th to the 860th [23]. In the inhibition, we talk about the Sildenafil mostly, because it's the most known (active ingredient in the Viagra®).

Structure of catalytic siteStructure of catalytic site

The only catalytic fragment is effective, so the regulations sites and the dimerization to a trimeric enzyme are useless for the catalytic activity. Moreover, this catalytic moiety has the same activity that the wild-type enzyme, so maybe the enzyme is monomeric in the cell [24]. Catalytic domain is conserved for the PDE family, between 20% and 40%, and the variant reactions of the PDE inhibitors on the different PDEs may be caused by the more variant regulatory sites [25].
The catalytic domain has 3 helical subdomains [24]:

• A N-terminal cyclin-fold region with eight helixes [26]: 5 α-helixes (1, 3, 5, 6 and 8) and 3 310-helixes (2,4, and 7),.
  
• A linker domain: two antiparallels α9 and α10 helixes, and between a disordered region,.
  
• A C-terminal buddle pocket with eight helixes: 5 long α-helixes (11, 12, 14, 17 and 18) and 3 smaller helixes (13, 15 and 16),.
  
  • α5, 6 and 8 surround α3 and form an interface with the linker domain and the CTD.
    

The catalytic site is a pocket which is 330Å in volume and a deep of 10Å, with a narrow entry. There are 4 regions: M (with 2 metallic ions), H (hydrophobic), Q (for the substrate), L (the lid or “H-Loop” on both N-term and linker domain). M site is surrounded by the helixes α6, 8, 9, 10 and 12. A majority of aliphatic or hydrophobic residues, that creates the hydrophobic pocket [2].

M site contains:

• The Me-1 and Me-2 sites are occupied by metal ions, Zinc within Me-1 and within Me-2, Zinc, Magnesium or Manganese [5],
  
• The residues and two H2O (W1 et W2) binding zinc:
  
  • The crucial [3] and the conserved His617 and 653[4], which bind one Zinc ion, are fundamental for the catalytic activity.
    
  • is critical for catalytic activity, but it isn't implied in the formation of the hydrophobic pocket. In fact, even if are lost and so the Zn not bound, a massive addition of Manganese[4] in the medium allows a reactivation of catalysis.
    
• W2 binds [24],
  
• And there are 3 hydrogen bonds between 3 H2O and the conserved resides [24].
  

Q site contains:

• In particular the conserved residues
  
• The hydrogen bonds, between , imply an interaction between and the cGMP purine. Thus, it improves the specificity for the cGMP, against cAMP. [24]
  
• And bind the cGMP through this pyrazol ring and π-π interactions between Gln817 and the phenyl ring. [24]
  
  • So, the conserved hydrophobic residue is critical in the maintaining of the affinity. [3]
    

H site:

• In particular the residues . [24]
  

L site:

• In particular the hydrophobic residues . [24]
  

Besides, the kcat of the catalytic fragment decreases 40-fold and 8-fold if the residues are mutated, and so there are important in the catalytic activity [5,3]. Two others residues are significant: which is important for cGMP affinity but have no impact on cAMP affinity H-loop [8] and the conserved which is important for substrate affinity and catalytic activity because it determinates H-loop conformation [21] (see below).
H-loop is important in the substrate recognition and the interactions with, it is . H-loop has the same interactions with cGMP and Sildenafil (cf. Inhibitor) because it's related to its role of substrate binding[21]. But The H-loop is not well understood, because when it's modified, the enzyme's function is practically not modified.[7] But it also may have a role for inhibitor fixation.
Nowadays catalysis mechanism is not well know: there could be a, nucleophile attack of a water molecule on the substrate [6].

InhibitionInhibition

In the treatment erection dysfunction, the inhibitors Sildenafil, Vardenafil and Tadalafil are used, like in the pulmonary hypertension[6]. Sildenafil may cure sleeping trouble after a intercontinental travel [11], may help to recover neural liaisons after an injury (the motor function[12] and the sensory motor function[13]) and can be vascular effects.

• PDE5 inhibitors might help physical condition in Duchene muscular dystrophy[14], improve of cognitive function [9]and have antidepressant effect[10] , also they might have an artero[15] and endothelial cell protective effect[16] so they have cardiac protection effect[17] (controversial, cf. clinical trial “RELAX”), finally they slow tumer cell growth (Tadalafil-like)[18]
  
• There are other PDE5 inhibitors: IBMX, Icarisid II and Udenafil.
  
• No interaction between the M site and the inhibitors
  

For the Sildenafil:

• 3 parts (R1: pyrazolopyrimidinone group; R2: ethoxyphenyl; R3: methylpiperazine)
  
• It is bound near Metallic ions but does not interact with them.
  

Binding amino acid for the Sildenafil:

• R1 group have contacts with (2 hydrogen bounds, so it increases Sildenafil affinity), (Sildenafil stacks against it), (hydrogen bound so it increases Sildenafil affinity [24]), and [21]. And there is hydrophobic interactions between the pyrazol ring and residues [24].
  
• R2 group is in the H pocket and has Van der Waals bounds with . And interaction Pi-Pi between the phenyl ring and the Phe820.
  
• R3 group is in the L pocket and has contacts with Asn 662, Ser 663, Tyr 664, Ile 665 (in the H-loop), Leu 804, Phe 801
• Gly659 is modified by Sildenafil presence in PDE5, ϕ and φ angles are increased (from 76-105° to 104-109° for ϕ and from 3-22° to 139-141° for φ) and ω angle is not changed. [21]
  

H-loop:
For each inhibitor, H-loop take a different and originally (comparatively to other PDEs) tertiary structure (and there are also minor modifications of the N-loop (788-811) ):

• For an unliganded PDE5, H-loop take a coil conformation. [21]
  
• In case of Sildenafil binding, a turn and an 310 helix (from 672 to 675) appear, and residues from 668 to 676 are disordered. The all loop cover the active site (by migrate of 24 Å from unliganded PDE5 loop structure, so the active site become a closed pocket). [21]
  
• H-loop is less important in the interactions for Sildenafil and Icarisid II than cGMP.
  

RegulationRegulation

As it is written over, there are 2 regulatory domains (GAF A and GAF B). In cGMP pathway, PDE5 allows a negative feedback of the molecule: first, in presence of cGMP, it binds GAF A which stimulates the catalysis in the active site, and vice versa. Moreover, cGMP actives PKG which phophorylates PDE5, that is stimulated by the presence of cGMP on the GAF A or/and the active site. If the protein is not binding with cGMP but it is phophorylated, that stimulates the binding of cGMP on GAF A and the catalytic site. So cGMP presence overstimulates the catalysis [19]. And it also increase inhibitor's affinity[20] and without cGMP, inhibitor don’t bind the PDE5 [22].

The NO PathwayThe NO Pathway

In the penile erection example, the nervous cell and/or epithelial cells are produced Nitrogen Oxide (NO) by the NOS (NO synthetase) from L-arginine and O2. They release NO in the extracellular environment going into vascular smooth cells and binding the Guanylyl Cyclase. This enzyme synthesizes cGMP from GMP, which stimulates the PKG. Finally, the calcium level is lower and the muscle cell relaxes and the Corpus Cavernosum rigidity increases. The PDE5 regulates the cGMP level making a negative feedback and can stop the rigidity. [22]

</StructureSection>